AVEO Pharmaceuticals, Inc. (AVEO)’s major shareholder David Mott Acquires $2.12 million of the Company; Rubicon Minerals (TSE:RMX) Had 1 Bulls

April 11, 2018 - By rebbecca

Rubicon Minerals Corporation (TSE:RMX) Logo

Among 2 analysts covering Rubicon Minerals Corp. (TSE:RMX), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Rubicon Minerals Corp. had 15 analyst reports since August 17, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Thursday, October 22 by Canaccord Genuity. The firm has “Hold” rating given on Monday, August 17 by Canaccord Genuity. As per Friday, August 21, the company rating was upgraded by Canaccord Genuity. The rating was downgraded by BMO Capital Markets on Wednesday, November 4 to “Market Perform (Speculative)”. The stock of Rubicon Minerals Corporation (TSE:RMX) earned “Hold” rating by TD Securities on Monday, November 2. The firm has “Speculative Buy” rating by TD Securities given on Wednesday, January 11. See Rubicon Minerals Corporation (TSE:RMX) latest ratings:

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Ratings Coverage

Among 3 analysts covering AVEO Pharmaceuticals (NASDAQ:AVEO), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. AVEO Pharmaceuticals has $7 highest and $200 lowest target. $5.67’s average target is 133.33% above currents $2.43 stock price. AVEO Pharmaceuticals had 15 analyst reports since March 30, 2016 according to SRatingsIntel. The stock of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has “Buy” rating given on Thursday, March 29 by Piper Jaffray. The stock of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) earned “Buy” rating by FBR Capital on Tuesday, January 16. The rating was initiated by FBR Capital on Wednesday, March 30 with “Outperform”. As per Tuesday, March 13, the company rating was maintained by FBR Capital. The rating was maintained by Piper Jaffray with “Buy” on Wednesday, August 9. Piper Jaffray upgraded AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) rating on Monday, August 28. Piper Jaffray has “Buy” rating and $4.5 target. The rating was initiated by Piper Jaffray with “Overweight” on Thursday, May 19. The firm has “Buy” rating given on Thursday, December 7 by FBR Capital. The stock has “Buy” rating by FBR Capital on Monday, June 26. The rating was maintained by FBR Capital with “Buy” on Thursday, March 22.

The stock decreased 2.80% or $0.07 during the last trading session, reaching $2.43. About 2.84M shares traded or 45.39% up from the average. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has risen 351.31% since April 11, 2017 and is uptrending. It has outperformed by 339.76% the S&P500.

Investors sentiment increased to 2.81 in Q4 2017. Its up 1.49, from 1.32 in 2017Q3. It is positive, as 4 investors sold AVEO Pharmaceuticals, Inc. shares while 12 reduced holdings. 26 funds opened positions while 19 raised stakes. 59.55 million shares or 0.59% less from 59.90 million shares in 2017Q3 were reported. Cubist Systematic Strategies Limited Liability holds 0% or 800 shares in its portfolio. Guggenheim Cap Llc stated it has 0% of its portfolio in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). Atlantic Trust Group Ltd Company reported 2,000 shares. Schwab Charles Invest Mngmt reported 0% in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). Nea Mngmt Ltd Liability Corporation owns 16.36 million shares. 17,963 are owned by Sg Americas Limited Liability Co. Prelude Capital Mgmt Ltd Liability Com accumulated 0.03% or 131,501 shares. Pnc Fin Serv Grp reported 12,000 shares stake. State Street Corp owns 127,143 shares. Spark Investment Management Ltd Co owns 268,200 shares or 0.04% of their US portfolio. Eam Investors Ltd Liability Co has 626,499 shares for 0.23% of their portfolio. Jane Street Gp Ltd stated it has 28,547 shares or 0% of all its holdings. Principal Finance Group Inc holds 0% or 19,345 shares in its portfolio. Glg Partners Ltd Partnership holds 0% or 25,200 shares. Citadel Advsr Lc invested in 0% or 843,820 shares.

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The company has market cap of $374.59 million. The company's pipeline of product candidates include Tivozanib, a vascular endothelial growth factor to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF/c-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study. It currently has negative earnings. The Company’s development programs also comprise AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and the AV-353 platform for the potential treatment of pulmonary arterial hypertension.

After the disclosing of a form filled with Washington-based Security and Exchange Commission; an important and substantial insider trading deal became apparent. The major shareholder of Aveo Pharmaceuticals Inc, David Mott; made a huge transaction in the open market by buying 920,976 shares at the avg. market share price which was $2.3 of the public company worth near $2.12 million U.S. Dollars . Due to the significance of this acquisition, it will not remain disregarded. He owns 11.21% of the -company’s market cap with a total of 17.28 million shares.

It closed at $1.18 lastly. It is down 0.00% since April 11, 2017 and is . It has underperformed by 11.55% the S&P500.

Rubicon Minerals Corporation engages in the exploration and development of gold properties in Canada and the United States. The company has market cap of $77.71 million. It holds a 100% interest in Phoenix Gold project located in the Red Lake gold district in northwestern Ontario, Canada. It currently has negative earnings. The firm also holds interests in approximately 280 square kilometers of exploration ground in the Red Lake gold district; and approximately 900 square kilometers of mineral property interests in the Long Canyon gold district in the Nevada-Utah border.

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Institutional Positions Chart